AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03327532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardio-pulmonary and peritoneal ultrasound
Description: Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
Study NCT03380429 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensors
Description: Clip-on sensors will be fitted to electronically record the actuation data.
Study NCT02968602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline capsules taken twice daily for two weeks.
Study NCT02968602 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken twice daily for two weeks.
Study NCT03160937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets.
Study NCT03160937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets.
Study NCT00126750 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VA MI Plus Interactive
Description: The experimental intervention, customized to the individual clinician in real-time consists of Internet learning modules integrating case-based education with audit, feedback, and benchmarking of practice profiles.
Study NCT02647710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHAT Life Intervention
Description: HIV Prevention behavioral health intervention
Study NCT02647710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion Control
Description: Behavioral health intervention control
Study NCT02501122 — intervention group
Intervention type: OTHER
Intervention: Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database
Description: Utilizing these databases to assess standards for quality of care measures in adenotonsillectomy patients.
Study NCT02702128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours
Study NCT02702128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
Study NCT03211676 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theranova-500 dialyzer
Description: hemodialysis with Theranova-500 dialyzer.
Study NCT03211676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theranova-500 dialyzer
Description: hemodialysis with Theranova-500 dialyzer.
Study NCT03211676 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Elisio-21H
Description: hemodialysis with Elisio-21H dialyzer
Study NCT03211676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elisio-21H
Description: hemodialysis with Elisio-21H dialyzer
Study NCT04052217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penile Ring
Description: Penile Ring at base of penis
Study NCT04052217 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Penile Ring
Description: Penile Ring at base of penis
Study NCT03298386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic medication review with the STOPP/START tool
Description: The STOPP / START tool includes a list of 42 substances / drug classes whose prescription could be discontinued based on specific criteria (81 STOPP criteria: Screening Tool of Older Person's Prescriptions) and a list of 34 clinical situations involving consideration of the usefulness of a new prescription (START criteria: Screening Tool to Action the Right Treatment).
Study NCT03327532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample retrieved for biological assessment and biobanking
Description: Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
Study NCT03327532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone interview
Description: Telephone interview will be performed 3, 12 and 24 months after discharge from hospital
Study NCT03327532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urinary sample retrieved for biological assessment and biobanking
Description: Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital
Study NCT03327532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: jugular and renal ultrasound (optional)
Description: optional jugular and renal ultrasound performed within 72hours of admission and before discharge from hospital
Study NCT01402193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-radiotherapy commencement of Arimidex
Description: Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
Study NCT01402193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post radiotherapy commencement of Arimidex
Description: Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
Study NCT01402193 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
Study NCT03916692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Description: Meal replacement drink containing 200 kcal
Study NCT03916692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy smart Carbohydrate blend
Description: Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
Study NCT02098343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Description: Intravenous infusion.
Study NCT02098343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Description: Intravenous infusion.
Study NCT02329405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Study NCT02329405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03916692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Dextrose
Description: Liquid Dextrose drink of 200 kcal
Study NCT01179191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine sulfate and naltrexone hydrochloride (EMBEDA)
Description: Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
Study NCT02283528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker Hybrid
Description: Place Hybrid arch bars
Study NCT02283528 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erich
Description: Control group is Erich arch bars
Study NCT04279431 — intervention group
Intervention type: DEVICE
Intervention: EEG Recording
Description: EEG recording acquired on BrainScope One device.
Study NCT04279431 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive Tests
Description: Cognitive performance tests performed on BrainScope One device.
Study NCT04279431 — intervention group
Intervention type: OTHER
Intervention: Clinician Evaluation
Description: Clinician evaluation performed as part of standard of care at the clinical site.
Study NCT04279431 — intervention group
Intervention type: OTHER
Intervention: 22-item CSI
Description: Self assessed 22-item Concussion Symptom Inventory (CSI).
Study NCT00920439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PoliorixTM
Description: Single dose, intramuscular administration.
Study NCT00206674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: 6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
Study NCT02286284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apheresis for extracorporal removal of sFlt-1
Study NCT01783860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Study NCT01783860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Study NCT00455923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide
Description: Seretide
Study NCT00455923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flixotide
Description: Flixotide
Study NCT03224741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentive
Description: Subjects in this condition will be read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information.Iin addition, they will be told that if they will get tested for HIV/AIDS within the next two weeks, they will receive $10 (the US dollar became Ecuador's official currency in 2001).
Study NCT03224741 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information
Description: Subjects assigned to this condition are read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information. Then, they are invited to get tested in the next two weeks.
Study NCT03224741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Choice
Description: Subjects in this condition will receive the same information and flyer as in T1; in addition, they are told that they have the opportunity to express their intention to get tested for HIV/AIDS. To this aim, they will be given a sheet of paper and asked to tick one of two boxes. The first box will say I intend to get tested within the next two weeks, and the second will say I will consider getting tested within the next two weeks but I am not ready to commit at this time. They will also be asked to write their initials at the bottom of the sheet, and will be told to keep it. This is a form of soft commitment which has proven effective in other contexts (Bryan et al. 2010).
Study NCT02985567 — intervention group
Intervention type: OTHER
Intervention: Intraocular pressure evaluation
Description: Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
Study NCT03501407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: 1 or 2 blood samples will be collected from the patient.
Study NCT00206674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
Study NCT03501407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: skin biopsy
Description: A skin biopsy will be performed on the periphery of the erythema migrans
Study NCT04450979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bioactive hydrolysate
Description: Participants given a bioactive vegetable hydrolysate to take one dose each morning and one dose each evening for the duration of the study.
Study NCT04450979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bioactive hydrolysate
Description: Participants given a bioactive vegetable hydrolysate to take one dose each morning and one dose each evening for the duration of the study.
Study NCT01699399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water immersion
Study NCT01699399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water exchange
Study NCT01699399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air insufflation
Study NCT02248584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C, E and Zinc
Description: Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
Study NCT04335565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sugar replacements
Description: Participants will receive a solution of stevia before being administered a fixed meal (lunch). Glucose and insulin levels, and Visual analogue scale data will be collected.
Study NCT04335565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sugar replacements
Description: Participants will receive a solution of stevia before being administered a fixed meal (lunch). Glucose and insulin levels, and Visual analogue scale data will be collected.
Study NCT02860039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: High dose Trivalent Influenza Vaccine given intramuscular
Study NCT02860039 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Vaccine
Description: Standard dose Quadrivalent Influenza Vaccine given intramuscular
Study NCT02860039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02860039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02168205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsules
Study NCT02168205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Capsules
Study NCT02168205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco
Description: Cigarettes
Study NCT02269501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Study NCT02328404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50,000 IU vitamin D3
Description: Film-coated tablet Biodal 50,000 IU containing cholecalciferol 50,000 IU
Study NCT02328404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo film-coated tablet of Biodal 50,000 IU
Study NCT02362646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPC Intramyocardial Injection
Description: Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
Study NCT02362646 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control Solution
Study NCT03265483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium glycinate
Description: Oral administration of magnesium glycinate daily for 12 weeks
Study NCT03265483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of identical-appearing placebo daily for 12 weeks
Study NCT02428959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amyl Nitrite
Description: Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
Study NCT02275039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified vaccinia virus ankara vaccine expressing p53
Description: Given SC
Study NCT02275039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT02275039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT05073276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patient is randomized to the weightbearing group the day after surgery.
Study NCT05073276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patient is randomized to the weightbearing group the day after surgery.
Study NCT04512391 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound guided Erector Spinae Plane Block (ESPB)
Description: Ultrasound guided ESPB is applied at T4 vertebrae level, 3 cm lateral to mid-line where transverse process lies. After identification of transverse process, needle is advanced in plane and real time visualisation on ultrasound screen. When bonny contact is encountered, normal saline is injected for verification of placement, then, 25 ml %0,25 bupivacaine is injected plane between transverse process and erector spinae muscles.
Study NCT04218175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromobilization exercises
Description: Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.
Study NCT04475536 — intervention group
Intervention type: DEVICE
Intervention: TANSEI stent
Description: stenting with the TANSEI sirolimus-eluting stent
Study NCT02803138 — intervention group
Intervention type: DRUG
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Co-formulated tablet
Study NCT02803138 — intervention group
Intervention type: DRUG
Intervention: Dasabuvir
Description: Tablet
Study NCT02803138 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Tablet
Study NCT02803138 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient support program
Description: Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.
Study NCT03955718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motherly App
Description: The Motherly app is a behavioral intervention aimed at preventing maternal depression and promoting child development.
Study NCT03955718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational App (Active Control)
Description: An app with educational content about gestation, maternal health and mental health, child development, etc.
Study NCT03834961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib Sulfate
Description: Given PO or via NG or G tube
Study NCT03388528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Residue Diet Intervention
Description: All patients will be provided with a LRD plan (\< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
Study NCT04356092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2D perfusion digital subtraction angiography of the foot.
Description: 2D perfusion digital subtraction angiography of the foot was performed after infrapopliteal angioplasty and Perfusion Blood Volume (PBV), Mean Transit Time (MTT), and Perfusion Blood Flow (PBF) maps were extracted by analyzing Time-Intensity Curves and signal intensity on the perfused vessel mask.
Study NCT04262024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education
Description: Women with hyperprolactiemia scheduled for cabergoline therapy 1.5-2 mg/week). for one month will be offered health education to help minimize prolactin level(group A)
Study NCT04262024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cabergoline 1.5-2 mg/week).orally daily for 1 month without health education
Description: Women with hyperprolactiemia scheduled for cabergoline 1.5-2 mg/week).for one month will not be offered health education (group B)